Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Nicola Tang
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 7on tracked calls
- Challenge rate
- 14%1 of 7 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 1 company
IFFInternational Flavors & Fragrances7 questions · 7 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
What are your expectations for free cash flow conversion for 2026 and also on a go-forward basis ex the Food Ingredients business?
Show response
DeVeau, while less specific, said full-year 2026 free cash flow will still exceed 2025 despite a potential couple-hundred-million working-capital headwind from the Food Ingredients stand; Remainco cash conversion mid-to-high teens.
Calendar 2026 Q1
what assumptions on both pricing and input inflation you're baking into your top line and EBITDA outlook
Show response
DeVeau detailed inflation across energy and logistics (double-digit increases, real-time impact) with raw material inflation expected later in year. Inventory provides short-term protection. Surcharges underway with full offset expected over 12-18 months, consistent with historical cycles.
Calendar 2025 Q4
I was wondering if you could provide some color on your assumptions behind the top and bottom end of your 1% to 4% currency-neutral sales outlook
Show response
DeVeau explained guidance assumes current market conditions. Higher end requires broader volume normalization. Q4 was marginally better than expected driven by new wins. All three core businesses and Food Ingredients expected to grow within range.
Calendar 2025 Q3
The bottom end, so the 1% currency-neutral growth implies a negative low single digit for Q4 versus the flat year-on-year that you did in Q3 despite slightly easier comps
Show response
DeVeau attributed cautious Q4 outlook to macro-driven volume weakness in Food Ingredients and HPC. Noted Fragrance Ingredients and Health North America combined are only about 5% of total company sales. Cautiously optimistic on 2026 acceleration.
Calendar 2025 Q2
Could you talk how integrated are the activities within food ingredients overall? And do you expect any standard costs from the Bunge deal?
Show response
DeVeau confirmed some stranded costs from Bunge sale already being addressed. Proactively working on Food Ingredients stand-alone cost structure for strategic flexibility, learning from Pharma Solutions where stranded costs were addressed too late.
Calendar 2025 Q1
Can you talk us through which areas of the portfolio could potentially be at risk and which parts could be more resilient in a recessionary scenario
Show response
Erik identified fine fragrances, consumer fragrances in beauty/hair care, and probiotics as discretionary areas. Confirmed order book remains in line with guidance.
Calendar 2024 Q4
Would you be able to talk a little bit more about what you expect across the core divisions
Show response
Erik confirmed growth will be primarily volume-driven with modest pricing, led by HNB, scent, and taste, with food ingredients more focused on margins.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| IFF International Flavors & Fragrances | 7 | 14%1 of 7 questions |
- IFFInternational Flavors & Fragrances · 7 questions14%1 of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 100%1 of 1 question | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 100% (1 of 1 question) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Cost Pressure3
- Demand3
- Revenue Growth2
- Macroeconomic2
- Capital Allocation1
- Pricing1
- M&A1